Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05387733 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas
A Phase 2 study, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05387733 is a Phase 2 study that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 12 participants.
The verdict
NCT05387733, a Phase 2 study, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This Phase 2 study will be an open-label and randomized study to assess the efficacy and safety of CBL-514 in participants with Dercum's Disease lipomas.
Interventions
- DRUG 10 mg CBL-514 per injection
- DRUG 15 mg CBL-514 per injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05387733
The ClinicalTrials.gov registry entry for NCT05387733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 10 mg CBL-514 per injection is the first listed.
NCT05387733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05387733 about?
NCT05387733 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas". This Phase 2 study will be an open-label and randomized study to assess the efficacy and safety of CBL-514 in participants with Dercum's Disease lipomas.
What is the current status of trial NCT05387733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-10-03. Estimated completion is 2023-04-03.
What interventions are being tested in trial NCT05387733?
The interventions under investigation include: 10 mg CBL-514 per injection (DRUG), 15 mg CBL-514 per injection (DRUG).
Who is sponsoring clinical trial NCT05387733?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.